Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention GLP-1, the most common co-covered peer. DGAT-2 appears in 1 tracked Cross-Sector story from February 24, 2026. The tracked stories average 5 original sources each.
1 verified story tracked
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention GLP-1, the most common co-covered peer. DGAT-2 appears in 1 tracked Cross-Sector story from February 24, 2026. The tracked stories average 5 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DGAT-2. Shared-story counts are live from our verified record — not editorial picks.
Patent Extension
Secured Rezdiffra patent protection through 2045.
DGAT-2 and siRNA Expansion
Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
GLP-1 Acquisition
Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Rezdiffra Commercial Launch
First full year of Rezdiffra availability in the U.S. market for MASH.
Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
